Fulcrum Therapeutics Inc

NASDAQ:FULC 4:00:00 PM EDT

3.15

+0.01 (+0.32%)

5:00:00 PM EDT: $3.15 0.00 (0.00%)

Market Cap (Intraday)	194.54M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$1.07 Million
Adjusted EPS	-$0.46

See more estimates

10-Day MA	$3.83
50-Day MA	$9.40
200-Day MA	$7.46

See more pivots

Fulcrum Therapeutics Inc Stock, NASDAQ:FULC

26 Landsdowne Street, Cambridge, Massachusetts 02139

United States of America

Phone: +1.617.651.8851

Number of Employees: 89

http://www.fulcrumtx.com

Description

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.